THE ROLE OF DRY POWDER INHALERS IN MODERN ASTHMA AND COPD MANAGEMENT: THE COMBINATION OF BUDESONIDE AND FORMOTEROL FUMARATE

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic respiratory
diseases, in which inhalation therapy plays a central role. Dry powder inhalers (DPIs), recommended by the Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, are suitable for most patients. An inspiratory flow rate (PIF) of ≥ 30 L/min is sufficient to ensure effective DPI dose delivery. Studies demonstrate that patients with asthma or COPD are generally able to achieve adequate PIF, and DPIs provide consistent budesonide dosing regardless of environmental conditions (temperature, humidity), mechanical stress, or variations in inhalation manoeuvers. The combination of budesonide and formoterol fumarate improves lung function parameters, patient-reported quality of life, and disease control, making it an effective, reliable, and patient-friendly treatment option in everyday clinical practice.